NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: C000000175

Registered date:12/09/2005

Pegylated IFN alpha-2b/Ribavirin therapy for chronic hepatitis C with genotype Ib, high titer-analysis with viral clearance.

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedChronic hepatitis C
Date of first enrollment2005/01/01
Target sample size250
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Negative for HCVRNA at 4 weeks of therapy. PEG-IFN alpha-2b/ribavirin (48weeks) Positive for HCVRNA at 4 weeks of therapy. PEG-IFN alpha-2b/ribavirin (48 weeks) Positive for HCVRNA at 4 weeks of therapy. PEG-IFN alpha-2b/ribavirin (48 weeks) plus IFN alpha-2b (24weeks)

Outcome(s)

Primary OutcomeSustained virological response rate
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum70years-old
GenderMale and Female
Include criteria
Exclude criteria(1)Complicated with other liver diseases such as autoimmune hepatitis and alcoholic liver injury. (2)Liver cirrhosis, hepatic failure. (3)Drug allergy for IFN or ribavirin. (4)Drug allergy for vaccine. (5)Administration of other anti-viral or immunomodulatory treatment. (6)Pregnancy. (7)Depression. (8)Complicated with autoimmune disorders.

Related Information

Contact

public contact
Name Satoru Kakizaki
Address 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan Japan
Telephone 027-220-8127
E-mail kakizaki@showa.gunma-u.ac.jp
Affiliation Gunma University Graduate School of Medicine Department of Medicine and Molecular Science
scientific contact
Name Hitoshi Takagi
Address 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan Japan
Telephone 027-220-8127
E-mail htakagi@med.gunma-u.ac.jp
Affiliation Gunma University Graduate School of Medicine Department of Medicine and Molecular Science